BioNTech SE is a global next generation immunotherapy company focused on developing novel medicines for cancer, infectious diseases and other serious conditions. The company leverages messenger RNA technology, protein based therapeutics and a fully integrated model that spans research, drug discovery, clinical development, manufacturing and commercialization. Its pipeline includes mRNA based vaccines, individualized neoantigen therapies, bispecific antibodies and antibody drug conjugates. BioNTech SE’s first approved product is the COVID 19 vaccine Comirnaty, which it co developed with Pfizer and has been authorized in more than 180 countries and regions, with over 5 billion doses shipped globally as of March 2026. The company has built a broad toolkit across multiple technology platforms, including a diverse range of potentially first in class therapeutic approaches such as mRNA immunotherapies and protein based therapeutics.

BioNTech SE generates revenue primarily from the sale of its COVID 19 vaccine Comirnaty in Germany and Turkey and from collaboration and licensing agreements with partners such as Pfizer, Bristol Myers Squibb, Genentech and others. These agreements provide upfront payments, milestone based payments and royalties on net sales of co developed products. For example, the collaboration with Bristol Myers Squibb includes an upfront payment of $1.5 billion and potential milestones worth up to $7.6 billion. The agreement with Pfizer for the COVID 19 vaccine includes an upfront payment and potential milestones up to $563 million. In 2025 the company reported approximately €17.2 billion in total cash, cash equivalents and security investments, reflecting strong financial performance. Additionally, BioNTech SE anticipates future revenue from its oncology and infectious disease pipeline candidates upon regulatory approval and commercial launch.

BioNTech SE holds a leading position in the mRNA vaccine market, demonstrated by its market share of over 50% in the global COVID 19 vaccine market during the 2025/2026 season. The company competes with firms such as Moderna, Pfizer (in certain markets), and other biotechnology companies developing cancer immunotherapies and infectious disease vaccines. Its competitive advantages include a proprietary mRNA platform with advanced lipid nanoparticle formulations, a broad pipeline that includes 16 oncology clinical programs and multiple infectious disease candidates, extensive manufacturing capabilities with facilities capable of producing up to 3 billion mRNA doses annually, and strategic collaborations with major pharmaceutical firms that provide financial support, co development expertise and global commercial reach. The company operates GMP certified manufacturing facilities in Germany, China, Rwanda and Australia, with its Marburg site capable of producing up to 3 billion mRNA doses per year.

BioNTech SE’s customers include government health agencies, public and private hospitals, clinics, and pharmacies that purchase its COVID 19 vaccine Comirnaty for national immunization programs. The company also supplies vaccine to international organizations through agreements with entities such as the European Commission, the World Health Organization, and various national ministries of health. In addition, its collaboration partners serve as customers for its clinical supply and co commercialization activities, notably Pfizer for COVID 19 vaccine distribution outside Germany and Turkey and Bristol Myers Squibb for the investigational bispecific antibody pumitamig. Furthermore, BioNTech SE engages with healthcare providers and researchers to support clinical trials of its pipeline candidates across oncology and infectious disease indications. Specific customers for its COVID 19 vaccine include the European Commission, national health ministries and private distributors in Germany and Turkey.